Production (Stage)
Black Diamond Therapeutics, Inc.
BDTX
$1.99
-$0.06-2.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 63.67% | -41.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.91% | -15.44% | |||
| Operating Income | 455.71% | 15.44% | |||
| Income Before Tax | 453.72% | -2.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 453.72% | -2.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 453.72% | -2.75% | |||
| EBIT | 455.71% | 15.44% | |||
| EBITDA | 458.26% | 15.51% | |||
| EPS Basic | 453.36% | -2.58% | |||
| Normalized Basic EPS | 507.30% | 11.68% | |||
| EPS Diluted | 447.03% | -2.58% | |||
| Normalized Diluted EPS | 500.13% | 11.68% | |||
| Average Basic Shares Outstanding | 0.10% | 0.18% | |||
| Average Diluted Shares Outstanding | 1.88% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||